ARCA biopharma Announces Third Quarter 2022 Financial Results Posted on October 28, 2022 by ARCA IT - Press Release 2022-Q3-Financial-Results-and-Business-Update-FINALDownload
ARCA biopharma Announces Second Quarter 2022 Financial Results Posted on August 3, 2022 by ARCA IT - Press Release, Uncategorized 2022-Q2-Financial-Results-and-Business-Update-FINALDownload
JACOB MA-WEAVER JOINS ARCA BIOPHARMA BOARD OF DIRECTORS Posted on June 21, 2022 by ARCA IT - Press Release, Uncategorized 6.21-Jacob-Ma-Weaver-Joins-BOD-FINAL
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review Posted on May 5, 2022 by ARCA IT - Press Release, Uncategorized 5.4-ARCA-Retains-Ladenburg-Thalmann
ARCA biopharma Announces First Quarter 2022 Financial Results Posted on May 2, 2022 by ARCA IT - Press Release, Uncategorized 5.2-2022-Q1-Financial-Results-and-Business-Update
ARCA biopharma Establishes Special Committee of the Board of Directors Posted on April 18, 2022 by ARCA IT - Press Release, Uncategorized 4.18-BOD-Strategic-Planning-Committee
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2B Clinical Trial Posted on March 31, 2022 by ARCA IT - Press Release, Uncategorized 3.31-ASPEN-COVID-19-Phase-2B-Data-FINAL
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update Posted on March 14, 2022 by ARCA IT - Press Release, Uncategorized 3.14-2021-Financial-Results-and-Business-Update
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2 Posted on January 4, 2022 by ARCA IT - Press Release, Uncategorized 1.4-Gencaro-Data-Published-in-Heart-Rhythm-O2
ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 Posted on December 2, 2021 by ARCA IT - Press Release, Uncategorized 12.2-ASPEN-COVID-19-trial-enrollment-completion